| abstract |
The present invention relates to new compounds of the formula (I), wherein Z is N; Y is CONR5, NR5CO, SO2NR5, NR5SO2, CH2NR5, NR5, NR5CONR5, CH2CO, CO, O or CH2O; X is CH or N; P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and the 5 or 6 phenyl ring or heteroaromatic ring may optionally be fused to a saturated, partially saturated or unsaturated ring 5 or 6 members containing one or more selected atoms of C, N, O or S; Q is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms, a process for its preparation and new intermediary products used therein, to pharmaceutical formulations containing the compounds therapeutically active and the use of active compounds in therapy, such as providing compounds that have a selective inhibition effect on GSK3. |